[go: up one dir, main page]

WO2006000350A2 - Compositions cosmetiques contenant des hydrolysats de proteines - Google Patents

Compositions cosmetiques contenant des hydrolysats de proteines Download PDF

Info

Publication number
WO2006000350A2
WO2006000350A2 PCT/EP2005/006556 EP2005006556W WO2006000350A2 WO 2006000350 A2 WO2006000350 A2 WO 2006000350A2 EP 2005006556 W EP2005006556 W EP 2005006556W WO 2006000350 A2 WO2006000350 A2 WO 2006000350A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
hydrolysate
peptides
protein
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/006556
Other languages
English (en)
Other versions
WO2006000350A3 (fr
Inventor
Juergen H. Vollhardt
Philippe Emmanuel Maillan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Priority to KR1020127034054A priority Critical patent/KR101371911B1/ko
Priority to US11/597,165 priority patent/US20080063674A1/en
Priority to AT05770871T priority patent/ATE551048T1/de
Priority to EP05770871A priority patent/EP1922054B1/fr
Priority to CN2005800214419A priority patent/CN1976676B/zh
Priority to ES05770871T priority patent/ES2380940T3/es
Priority to JP2007518495A priority patent/JP2008504319A/ja
Publication of WO2006000350A2 publication Critical patent/WO2006000350A2/fr
Publication of WO2006000350A3 publication Critical patent/WO2006000350A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners

Definitions

  • the present invention is directed to cosmetic compositions containing specific protein hydrolysates which are rich in proline on one end of the peptide, in particular which are rich in carboxy terminated proline.
  • the cosmetic compositions are particularly useful for treating wrinkles, moisturizing the skin but also for thickening the epidermis, protecting and repairing the skin's lipid barrier and for hair care compositions.
  • Cosmetic preparations are essentially useful for skin care.
  • One aim of skin care in the cosmetic sense is to strengthen or rebuild the skin's natural function as a barrier against environmental influences (e.g. UV-light, dirt, chemicals, microorganisms) and against the loss of endogenous substances (e.g. water, natural lipids, electrolytes). If this function becomes impaired, increased resorption of toxic or allergenic substances or attack by microorganisms may result, leading to toxic or allergic skin reactions.
  • Another aim of skin care is to compensate for the loss by the skin of lipids and water caused by daily washing. This is particularly important, if the natural regeneration ability is inadequate. Furthermore, skin care products should protect against environmental influences, in particular against sun and wind, and delay skin aging. Also dry air conditions which occur particularly in winter tend to reduce the moisture content of the skin. Already this effect leads to a reduced smoothness and a dull skin surface. It is therefore important for a cosmetic skin care product to replenish the skin moisture content and to provide ingredients preventing the loss of moisture. Furthermore dry skin is prone more deleterious effects leading to age phenomena and sensory discomfort, like itching or stinging. It is therefore one goal of the present invention to provide safe materials to counteract these effects.
  • TEWL transepidermal water loss
  • Another strategy to fight wrinkles is to stimulate the collagen synthesis in the dermis.
  • a number of degenerative processes act on the collagen matrix and is triggered by extrinsic factors like UV radiation, pollution in general and particular cigarette smoke or intrinsic factors leading to any chronic or subchronic inflammation.
  • Destruction and/or impaired repair efficacy leads to a more dense and less elastic macro structure of the dermis, which in turn leads to the formation of deep wrinkles.
  • Enhancing the de novo synthesis of collagen or other structural proteins of the dermis is considered a valuable therapy to reduce the existing wrinkles and to protect against the appearance of new wrinkles.
  • the problem to be solved by the present invention is providing cosmetic compositions having excellent cosmetic properties which can usually be achieved by adding protein hyrolysates to cosmetic compositions but which have a low or no risk of causing allergic reactions by consumers.
  • the compositions should have a favorable balance between cosmetic effects and risk of skin adverse reactions.
  • the invention provides low odor and low color hydrolysis products, which are compatible with most cosmetic formulations including low fragrance containing products.
  • the present invention provides a cosmetic composition containing a protein hydrolysate which has a high content of peptides with a terminal protein and a cosmetically acceptable excipient.
  • the protein hydrolysate is preferably a protein hydrolysate which comprises peptides, wherein the molar fraction of peptides (%) carrying a carboxy terminal praline is more than two times higher than the molar fraction (%) of proline in the protein substrate used to generate the hydrolysate.
  • the protein hydrolysate is furthermore preferably
  • a whey hydrolysate which comprises peptides wherein the molar fraction of peptides carrying a carboxy terminal proline is at least 8%, preferably at least 15%, more preferably from 30 to 70% and/or a casein hydrolysate which comprises peptides wherein the molar fraction of peptide carrying a carboxy terminal proline is at least 25%, preferably at least 30% and more preferably less than 70% and/or a soy hydrolysate which comprises peptides wherein the molar fraction of peptide carrying a carboxy terminal proline is at least 20%, preferably from 30 to 70% and/or a gluten hydrolysate which comprises peptides wherein the molar fraction of peptide carrying a carboxy terminal proline is at least 20%, preferably at least 30%, advantageously less than 70% and/or a barley hydrolysate which comprises peptides wherein the molar fraction of peptide carrying a carboxy terminal proline is at least 20%, preferably at least 30%; advantageously
  • the protein hydrolysate having a high content of peptides with a terminal proline is a protein hydrolysate which is rich in tripeptides, whereby the tripeptides are rich in proline at one end of the peptide.
  • the protein hydrolysates for use in the cosmetic compositions of the present invention are well-known in the prior art.
  • the protein hydrolysates for use in the cosmetic compositions of the present invention are well-known in the prior art.
  • whey hydrolysate which comprises peptides wherein the molar fraction of peptides carrying a carboxy terminal proline is at least 8%, preferably at least 15%, more preferably from 30 to 70%; casein hydrolysate which comprises peptides wherein the molar fraction of peptide carrying a carboxy terminal proline is at least 25%, preferably at least 30% and more preferably less than 70%; soy hydrolysate which comprises peptides wherein the molar fraction of peptide carrying a carboxy terminal proline is at least 20%, preferably from 30 to 70%; gluten hydrolysate which comprises peptides wherein the molar fraction of peptide carrying a carboxy terminal proline is at least 20%, preferably at least 30%, advantageously less than 70% and barley hydrolysate which comprises peptides wherein the molar fraction of peptide carrying a carboxy terminal proline is at least 20%, preferably at least 30%, advantageously less than 70%, and a process for producing such protein hydrolysates are known
  • the protein hydrolysate is preferably a protein hydrolysate which comprises peptides, wherein the molar fraction of peptides (%) carrying a carboxy terminal proline is more than two times higher than the molar fraction (%) of proline in the protein substrate used to generate the hydrolysate, and such a protein hydrolysate is also known from these documents. Reference is made to these documents in particular regarding the preparation of the protein hydrolysates which is described in the documents in detail.
  • Protein hydrolysates which are rich in tripeptides, whereby the tripeptides are rich in proline at one end of the peptide are known from WO 03/102195, and this document is also incorporated herein by reference. It is referred to WO 03/102195 in particular regarding the process for producing the protein hydrolysates which are rich in tripeptides, whereby the tripeptides are rich in proline at one end of the peptide, and regarding further preferred protein hydrolysates.
  • the preferred protein hydrolysates of the present invention are also the preferred protein hydrolysates disclosed in WO 03/102195.
  • Protein hydrolysates which can be used for the cosmetic compositions of the present invention can also be prepared with the novel proteolytic enzymes disclosed in WO 02/068623, and this document is also incorporated herein by reference regarding preferred production methods of protein hydrolysates which can be used for the cosmetic compositions of the present invention.
  • the present invention provides cosmetic compositions containing a protein hydrolysate with a high content of terminal proline which is known from WO 03/102195, WO 02/45523 and/or WO 02/45524.
  • protein hydrolysates which are rich in tripeptides, whereby the tripeptides are rich in proline at one end of the peptide, wherein the peptide has a carboxy terminal proline as disclosed in WO 03/102195.
  • These hydrolysates may optionally also comprise dipeptides.
  • a protein hydrolysate which is rich in tripeptides, wherein the tripeptides are rich in proline at one end of the peptide, preferably the carboxyl end of the peptide, wherein at least 20 molar%, more preferably at least 25 molar%, still more preferably at least 30 molar% of the peptides having a molecular weight of 200 to 2000 Dalton is present in the hydrolysate as tripeptide.
  • protein hydrolysates as used in this specification also encompasses the above precursor products.
  • whey hydrolysate which comprises peptides wherein the molar fraction of peptides carrying a carboxy terminal proline is at least 8%, preferably at least 15%, more preferably from 30 to 70% casein hydrolysate which comprises peptides wherein the molar fraction of peptide carrying a carboxy terminal praline is at least 25%, preferably at least 30% and more preferably less than 70% soy hydrolysate which comprises peptides wherein the molar fraction of peptide carrying a carboxy terminal proline is at least 20%, preferably from 30 to 70% gluten hydrolysate which comprises peptides wherein the molar fraction of peptide carrying a carboxy terminal proline is at least 20%, preferably at least 30%, advantageously less than 70% and barley hydrolysate which comprises peptides wherein the molar fraction of peptide carrying a carboxy terminal proline is at least 20%, preferably at least 30%, advantageously less than 70%, and the protein hydrolysate which is a protein hydrolysate
  • the protein hydrolysate as defined above comprises peptides, wherein the molar fraction of peptides (%) carrying a carboxy terminal proline is at least two times, more preferably at least three times, the molar fraction (%) of praline in the protein substrate used to produce the hydrolysates.
  • the average length of the peptides in the protein hydrolysates is from 3 to 9 amino acids.
  • Preferred hydrolysates are a whey hydrolysate which comprises peptides wherein the molar fraction of peptides carrying a carboxy terminal proline is at least 8%, preferably at least 15%, more preferably from 30 to 70%, a casein hydrolysate which comprises peptides wherein the molar fraction of peptide carrying a carboxy terminal proline is at least 25%, preferably from 30 to 70%, and a soy hydrolysate which comprises peptides wherein the molar fraction of peptides carrying a carboxy terminal proline is at least 20%, preferably from 30 to 70%.
  • protein hydrolysates wherein at least 10% of the protein substrate is hydrolyzed, preferably wherein from 20 to 90% of the protein substrate is hydrolyzed.
  • peptides or peptide fragments it is preferably meant peptides with molecular masses from 400 to 2000 Dalton. These peptides can be analyzed according to the LC/MC analysis as described in WO 02/45523.
  • the protein substrate is substantially hydrolyzed, advantageously for at least 50%.
  • at least 10% of the protein substrate is converted into peptides having molecular masses from 400 to 2000 Dalton. More preferably from 20 to 90% and even more preferably from 30 to 80% of the protein substrate is converted into such peptides.
  • a protein substrate may be incubated with an enzyme mixture comprising an isolated, purified proline-specific endoprotease, a serine endoprotease or a metallo endoprotease and a carboxypeptidase to produce a protein hydrolysate enriched in peptide fragments having a carboxy terminal proline as disclosed in WO 02/45523.
  • the enzyme mixture of WO 02/45523 which is preferably used in the present invention is characterized in that it contains at least one endoprotease for example a serine protease or a metallo endoprotease in conjunction with a proline-specific endoprotease (E. C. 3.4..21.26) to provide a primary hydrolysate.
  • endoprotease for example a serine protease or a metallo endoprotease in conjunction with a proline-specific endoprotease (E. C. 3.4..21.26) to provide a primary hydrolysate.
  • enriched hydrolysates may comprise at least 8%, preferably at least 15%, more preferably from 30 to 70% peptide fragments having a carboxy terminal proline residue.
  • These protein hydrolysates can be obtained by enzyme preparations which are capable of generating peptides bearing proline residues at carboxy termini, which are disclosed in WO 02/45523.
  • protein hydrolysates which can be obtained by a process corresponding to the process of example 1 of WO 02/45523, using a suitable substrate. Preferred are also mixtures of the protein hydrolysates disclosed in WO 02/45523 and in WO 03/102195.
  • Substrates for hydrolysis by an enzyme mixture include whole milk, skimmed milk, acid casein, rennet casein, acid whey products or cheese whey products.
  • the Aspergillus derived proline-specific endoprotease does not only cleave at the carboxy terminal side of proline residues but also at the carboxy terminal side of hydroxyproline residues which makes other, collagen-based animal proteins such as gelatin as well as bones or fishbones containing residual meat, interesting substrates for the enzyme.
  • vegetable substrates like wheat gluten, milled barley and protein fractions obtained from, for example, soy, rice or corn are suitable substrates. Milk protein hydrolysates produced according to WO 02/45523 may be used with or without additional filtration or purification steps.
  • the above-defined protein hydrolysates which have a high content of peptides with a terminal proline, have excellent activity in various cosmetic applications, while not causing the irritations of the skin which are caused by other protein hydrolysates produced by state of the art methods.
  • the cosmetic compositions containing the protein hydrolysates as defined above show activity in particular for treating and preventing wrinkles, moisturizing the skin and hair as well as thickening of the epidermis but also for ameliorating the effect of aging of the skin which may be caused by external or environmental hazards or by the natural aging of the skin.
  • the protein hydrolysates can also be used to prevent and repair damaged hair, to restructure and/or strengthen it. This is particular important for long or treated hair.
  • the cosmetic compositions are in particular compositions which can be used for treatment or prophylaxis of wrinkles or dry skin or sensitive skin or any symptoms caused by negative developments of the physiological homeostasis of healthy skin, promotion of hair growth, protection from hair loss, a thickening of the epidermis, anti-acne, the inhibition of senescence of skin cells, prevention or treatment of photodamage, prevention or treatment of oxidative stress phenomena, prevention or treatment of cellulite, prevention or treatment of pigmentation disorders and/or even the skin tone, prevention and treatment of disturbances in ceramide and lipid synthesis, prevention of excess sebum production, reduction of activities of matrix metallo proteases or other proteases in the skin, treatment and prevention of inflammatory skin conditions including atopic eczema, polymorphic light eruption, psoriasis, vertiligo, prevention and treatment of itchy or irritated skin as well as in hair care products or in compositions for applying to or treating nails, in particular finger nails.
  • composition of the present invention may contain UV-A and UV-B filters.
  • UV-B or broad spectrum screening agents i.e. substances having absorption maximums between about 290 and 340 nm, which are preferred for combination with the compounds of the present invention, are the following organic and inorganic compounds:
  • Benzotriazole derivatives such as 2,2'-methylene-bis-(6-(2H-benzotriazole-2- yl)-4-(1 ,1 ,3,3,-tetramethylbutyl)-phenol (TiNOSORB M) and the like;
  • phenylene-1 ,4-bis-benzimidazolsulfonic acids or salts such as 2,2-(1 ,4- phenylene)bis-(1 H-benzimidazol-4,6-disulfonic acid) (Neoheliopan AP);
  • Preferred emollients include mineral oils, lanolin, petrolatum, capric/caprylic triglyceraldehydes, cholesterol, silicones such as dimethicone, cyclomethicone, almond oil, jojoba oil, avocado oil, castor oil, sesame oil, sunflower oil, coconut oil and grape seed oil, cocoa butter, olive oil aloe extracts, fatty acids such as oleic and stearic, fatty alcohols such as cetyl and hexadecyl (ENJAY), diisopropyl adipate, hydroxybenzoate esters, benzoic acid esters of C 9- i 5 -alcohols, isononyl iso-nonanoate, ethers such as polyoxypropylene butyl ethers and polyoxypropylene cetyl ethers, and C 12- i 5 -alkyl benzoates, and mixtures thereof.
  • silicones such as dimethicone, cyclome
  • the most preferred emollients are hydroxybenzoate esters, aloe vera, C 12- i 5 -alkyl benzoates, and mixtures thereof.
  • An emollient is present in an amount of about 1 wt.% to about 20 wt.% of the total weight of the composition.
  • the preferred amount of emollient is about 2 wt.% to about 15 wt.%, and most preferably about 4 wt.% to about 10 wt.%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des compositions cosmétiques comprenant un hydrolysat de protéines et un excipient acceptable de manière cosmétique, ledit hydrolysat de protéines présentant un contenu élevé de peptides avec un proline terminal.
PCT/EP2005/006556 2004-06-28 2005-06-17 Compositions cosmetiques contenant des hydrolysats de proteines Ceased WO2006000350A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020127034054A KR101371911B1 (ko) 2004-06-28 2005-06-17 단백질 가수분해산물을 함유하는 화장품 조성물
US11/597,165 US20080063674A1 (en) 2004-06-28 2005-06-17 Cosmetic Composition Containing Protein Hydrolysates
AT05770871T ATE551048T1 (de) 2004-06-28 2005-06-17 Proteinhydrolysate enthaltende kosmetische zusammensetzungen
EP05770871A EP1922054B1 (fr) 2004-06-28 2005-06-17 Compositions cosmétiques contenant d'hydrolysats de protéine
CN2005800214419A CN1976676B (zh) 2004-06-28 2005-06-17 含有蛋白水解产物的化妆品组合物
ES05770871T ES2380940T3 (es) 2004-06-28 2005-06-17 Composiciones cosméticas que contienen hidrolizados de proteína
JP2007518495A JP2008504319A (ja) 2004-06-28 2005-06-17 タンパク質水解物を含有する化粧品組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04015155.7 2004-06-28
EP04015155 2004-06-28

Publications (2)

Publication Number Publication Date
WO2006000350A2 true WO2006000350A2 (fr) 2006-01-05
WO2006000350A3 WO2006000350A3 (fr) 2006-07-13

Family

ID=35432584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/006556 Ceased WO2006000350A2 (fr) 2004-06-28 2005-06-17 Compositions cosmetiques contenant des hydrolysats de proteines

Country Status (8)

Country Link
US (1) US20080063674A1 (fr)
EP (1) EP1922054B1 (fr)
JP (1) JP2008504319A (fr)
KR (2) KR101371911B1 (fr)
CN (1) CN1976676B (fr)
AT (1) ATE551048T1 (fr)
ES (1) ES2380940T3 (fr)
WO (1) WO2006000350A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1813257A1 (fr) * 2006-01-31 2007-08-01 Henkel Kommanditgesellschaft auf Aktien Composition de soin capillaire à base d'un hydrolysat de caséine.
WO2010071132A1 (fr) 2008-12-15 2010-06-24 カルピス株式会社 Peptide destiné à l'inhibition du vieillissement cutané
EP1813261A3 (fr) * 2006-01-30 2012-05-02 Henkel AG & Co. KGaA Méthode d'éclaircissement des fibres kératiniques
WO2014030125A3 (fr) * 2012-08-23 2014-04-10 Nutrición Técnica Deportiva, S.L. Utilisation d'un hydrolysat de caséine comme agent antiherpétique
EP2684558A4 (fr) * 2011-03-10 2014-10-22 Megmilk Snow Brand Co Ltd Agent embellissant la peau
GB2546852A (en) * 2015-11-20 2017-08-02 Henkel Ag & Co Kgaa Hair care agents containing casein hydrolysate for improving hair structure
WO2020127409A1 (fr) * 2018-12-19 2020-06-25 Société des Produits Nestlé S.A. Composition pour prévenir ou réduire la perte d'eau transépidermique et améliorer la fonction barrière de la peau

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101395370B1 (ko) 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
ES2755840T3 (es) 2007-03-22 2020-04-23 Berg Llc Formulaciones tópicas que tienen biodisponibilidad aumentada
EP2271325A4 (fr) 2008-04-11 2011-11-09 Cytotech Labs Llc Procédés et utilisation d'induction de l'apoptose dans des cellules cancéreuses
US20100255044A1 (en) * 2009-03-30 2010-10-07 Susan Daly Method of depositing particulate benefit agents on keratin-containing substrates
CN104825429A (zh) 2009-05-11 2015-08-12 博格有限责任公司 利用表观代谢转变剂(辅酶q10)治疗疾病的方法
KR101131706B1 (ko) * 2009-12-22 2012-04-03 애경산업(주) 모발 화장료 조성물
JP5627902B2 (ja) * 2010-02-26 2014-11-19 旭化成ケミカルズ株式会社 抗老化剤
SG183508A1 (en) 2010-03-12 2012-10-30 Berg Pharma Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
WO2012138765A1 (fr) 2011-04-04 2012-10-11 Berg Pharma Llc Méthodes de traitement de tumeurs du système nerveux central
PE20180414A1 (es) 2011-06-17 2018-03-01 Berg Llc Composiciones farmaceuticas inhalables
KR101805690B1 (ko) * 2011-06-27 2018-01-10 (주)아모레퍼시픽 화장료 조성물을 포함하는 피부 미용 키트 및 도포방법
JP6187461B2 (ja) * 2012-07-03 2017-08-30 味の素株式会社 保湿剤及びこれを含有する化粧料
CA2909094C (fr) 2013-04-08 2023-06-27 Berg Llc Methodes de traitement du cancer au moyen de polytherapies utilisant la coenzyme q10
WO2015035094A1 (fr) 2013-09-04 2015-03-12 Berg Llc Procédés de traitement du cancer par perfusion continue de coenzyme q10
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
WO2017165281A1 (fr) 2016-03-22 2017-09-28 Avicenna Nutraceutical, Llc Compositions de collagène hydrolysé et leurs procédés de fabrication
EP3624760B1 (fr) * 2017-05-19 2023-12-27 The Procter & Gamble Company Composition de soin capillaire comprenant des composés triester et des esters gras d'acide benzoïque
CN114028276B (zh) * 2021-12-17 2023-09-26 上海蜂花日用品有限公司 一种具有多效修护效果的护发组合物及其应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB906000A (en) 1959-11-23 1962-09-19 Hoffmann La Roche Cosmetic compositions comprising vitamin-a derivatives
EP0358584A1 (fr) 1988-09-09 1990-03-14 Rhone-Poulenc Chimie Diorganopolysiloxane à fonction benzalmalonate
EP0514491A1 (fr) 1990-02-14 1992-11-25 Oreal Composition cosmetique filtrante photostable contenant un filtre uv-a et un beta, beta-diphenylacrylate ou alpha-cyano-beta, beta-diphenylacrylate d'alkyle.
EP0538431A1 (fr) 1991-05-10 1993-04-28 Givaudan Roure Int Organosiloxanes utilises comme agents de protection solaire.
EP0699429A2 (fr) 1994-08-04 1996-03-06 F. Hoffmann-La Roche Ag Méthode pour favoriser la croissance des cheveux
EP0709080A1 (fr) 1994-10-14 1996-05-01 Givaudan-Roure (International) S.A. Composition cosmétique d'écran solaire photostable
US5605680A (en) 1986-12-08 1997-02-25 L'oreal Photostable cosmetic composition containing a UV-A screen and a UV-B screen and a process for stabilizing the UV-A screen with the UV-B screen
EP0780119A1 (fr) 1995-12-18 1997-06-25 Givaudan-Roure (International) S.A. Filtres solaires
EP0895776A2 (fr) 1997-08-05 1999-02-10 F. Hoffmann-La Roche Ag Composition cosmetique filtrante
EP1046391A2 (fr) 1999-04-20 2000-10-25 Basf Aktiengesellschaft Usage d'hydroxybenzophénones aminosubstituées comme filtres UV photostables dans des préparations cosmétiques et pharmaceutiques
WO2002045523A2 (fr) 2000-12-07 2002-06-13 Dsm Ip Assets B.V. Hydrolysats de proteines enrichis en peptides possedant un reste de proline a terminaison carboxy
WO2002068623A2 (fr) 2001-02-23 2002-09-06 Dsm Ip Assets B.V. Nouveaux genes codant les nouvelles enzymes proteolytiques
US6506732B1 (en) 1999-01-28 2003-01-14 Universite Laval Enzymatic hydrolysate of milk proteins
WO2003086342A1 (fr) 2002-04-12 2003-10-23 L'oreal Compositions cosmetiques, en particulier antirides, contenant des polymeres a lcst solubles ou dispersibles dans l'eau
WO2003102195A1 (fr) 2002-06-04 2003-12-11 Dsm Ip Assets B.V. Hydrolysat de proteines riche en tripeptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5810512A (ja) * 1981-07-09 1983-01-21 Nisshin Oil Mills Ltd:The 化粧料
JPS60192599A (ja) * 1983-11-30 1985-10-01 Fuji Oil Co Ltd オリゴペプチド混合物の製造法
US4670268A (en) * 1985-01-29 1987-06-02 Abbott Laboratories Enteral nutritional hypoallergenic formula
JP2959786B2 (ja) * 1990-01-05 1999-10-06 株式会社片山化学工業研究所 保湿剤
JP2834278B2 (ja) * 1990-05-18 1998-12-09 森永乳業株式会社 化粧料及び皮膚外用剤
JPH06199626A (ja) * 1992-12-28 1994-07-19 Yamakawa Boeki Kk 新規なオリゴペプチド含有美容製品調製用添加剤
JPH08169816A (ja) * 1994-12-16 1996-07-02 Kurooda Japan Kk 加水分解小麦蛋白質
JP3567350B2 (ja) * 1996-03-13 2004-09-22 株式会社ホーネンコーポレーション 抗脱毛症剤
CN1054505C (zh) * 1996-12-11 2000-07-19 林镇才 一种活性成份的化妆品添加剂
US7498310B1 (en) * 1998-08-13 2009-03-03 Beiersdorf Ag Cosmetic or dermatological preparations comprising oligopeptides for lightening the skin of age marks and/or for preventing tanning of the skin, in particular tanning of the skin caused by UV radiation
FR2784028B1 (fr) * 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques
JP2001039850A (ja) * 1999-07-27 2001-02-13 Shiseido Co Ltd コラーゲンゲル収縮促進剤
US6497889B2 (en) * 2000-06-20 2002-12-24 Kyowa Hakko Kogyo Co., Ltd. Cosmetics
JP2002020256A (ja) * 2000-06-30 2002-01-23 Noevir Co Ltd 皮膚外用剤
AU2002230397A1 (en) * 2000-10-10 2002-04-29 The Procter And Gamble Company Packaged scalp cosmetic compositions
JP2002284668A (ja) * 2001-03-26 2002-10-03 Cosmo Products Kk クスミの予防・治療剤
CN1231137C (zh) * 2001-07-18 2005-12-14 Dsmip资产有限公司 乳类蛋白质水解的方法
JP2004026730A (ja) * 2002-06-26 2004-01-29 Katayama Chem Works Co Ltd 制汗防臭剤
FR2854897B1 (fr) * 2003-05-12 2007-05-04 Sederma Sa Compositions cosmetiques ou dermopharmaceutiques pour reduire les signes du vieillissement cutane.

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB906000A (en) 1959-11-23 1962-09-19 Hoffmann La Roche Cosmetic compositions comprising vitamin-a derivatives
US5605680A (en) 1986-12-08 1997-02-25 L'oreal Photostable cosmetic composition containing a UV-A screen and a UV-B screen and a process for stabilizing the UV-A screen with the UV-B screen
EP0358584A1 (fr) 1988-09-09 1990-03-14 Rhone-Poulenc Chimie Diorganopolysiloxane à fonction benzalmalonate
EP0358584B1 (fr) 1988-09-09 1992-09-16 Rhone-Poulenc Chimie Diorganopolysiloxane à fonction benzalmalonate
EP0514491A1 (fr) 1990-02-14 1992-11-25 Oreal Composition cosmetique filtrante photostable contenant un filtre uv-a et un beta, beta-diphenylacrylate ou alpha-cyano-beta, beta-diphenylacrylate d'alkyle.
EP0538431A1 (fr) 1991-05-10 1993-04-28 Givaudan Roure Int Organosiloxanes utilises comme agents de protection solaire.
EP0538431B1 (fr) 1991-05-10 1996-02-28 Givaudan-Roure (International) S.A. Organosiloxanes utilises comme agents de protection solaire
EP0699429A2 (fr) 1994-08-04 1996-03-06 F. Hoffmann-La Roche Ag Méthode pour favoriser la croissance des cheveux
EP0709080A1 (fr) 1994-10-14 1996-05-01 Givaudan-Roure (International) S.A. Composition cosmétique d'écran solaire photostable
EP0780119A1 (fr) 1995-12-18 1997-06-25 Givaudan-Roure (International) S.A. Filtres solaires
EP0895776A2 (fr) 1997-08-05 1999-02-10 F. Hoffmann-La Roche Ag Composition cosmetique filtrante
US6506732B1 (en) 1999-01-28 2003-01-14 Universite Laval Enzymatic hydrolysate of milk proteins
EP1046391A2 (fr) 1999-04-20 2000-10-25 Basf Aktiengesellschaft Usage d'hydroxybenzophénones aminosubstituées comme filtres UV photostables dans des préparations cosmétiques et pharmaceutiques
WO2002045523A2 (fr) 2000-12-07 2002-06-13 Dsm Ip Assets B.V. Hydrolysats de proteines enrichis en peptides possedant un reste de proline a terminaison carboxy
WO2002045524A2 (fr) 2000-12-07 2002-06-13 Dsm Ip Assets B.V. Hydrolysats de proteine enrichis en peptides presentant un residu de proline a terminaison carboxy
WO2002068623A2 (fr) 2001-02-23 2002-09-06 Dsm Ip Assets B.V. Nouveaux genes codant les nouvelles enzymes proteolytiques
WO2003086342A1 (fr) 2002-04-12 2003-10-23 L'oreal Compositions cosmetiques, en particulier antirides, contenant des polymeres a lcst solubles ou dispersibles dans l'eau
WO2003102195A1 (fr) 2002-06-04 2003-12-11 Dsm Ip Assets B.V. Hydrolysat de proteines riche en tripeptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALLERGY, vol. 53, no. 11, November 1998 (1998-11-01), pages 1078 - 82
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, vol. 3, no. 8, 2002, pages 547 - 55
ARCHIVE OF DERMATOLOGY, vol. 112, no. 7, July 1976 (1976-07-01), pages 1008 - 9
CONTACT DERMATITIS, vol. 42, no. 6, June 2000 (2000-06-01), pages 360

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1813261A3 (fr) * 2006-01-30 2012-05-02 Henkel AG & Co. KGaA Méthode d'éclaircissement des fibres kératiniques
EP1813257A1 (fr) * 2006-01-31 2007-08-01 Henkel Kommanditgesellschaft auf Aktien Composition de soin capillaire à base d'un hydrolysat de caséine.
JP5653759B2 (ja) * 2008-12-15 2015-01-14 カルピス株式会社 皮膚老化抑制ペプチド
US20110092431A1 (en) * 2008-12-15 2011-04-21 Calpis Co., Ltd. Skin aging-inhibiting peptide
WO2010071132A1 (fr) 2008-12-15 2010-06-24 カルピス株式会社 Peptide destiné à l'inhibition du vieillissement cutané
US9067972B2 (en) 2008-12-15 2015-06-30 Calpis Co., Ltd. Skin aging-inhibiting peptide
EP2684558A4 (fr) * 2011-03-10 2014-10-22 Megmilk Snow Brand Co Ltd Agent embellissant la peau
US9255123B2 (en) 2011-03-10 2016-02-09 Megmilk Snow Brand Co., Ltd. Skin-beautifying agent
WO2014030125A3 (fr) * 2012-08-23 2014-04-10 Nutrición Técnica Deportiva, S.L. Utilisation d'un hydrolysat de caséine comme agent antiherpétique
US20150343010A1 (en) * 2012-08-23 2015-12-03 Ntd Labs, S.L. Use Of A Casein Hydrolysate As An Antiherpetic Agent
AU2013307236B2 (en) * 2012-08-23 2016-11-17 Ntd Labs, S.L. Use of a casein hydrolysate as an antiherpetic agent
US9662369B2 (en) 2012-08-23 2017-05-30 Ntd Labs, S.L. Use of a casein hydrolysate as an antiherpetic agent
GB2546852A (en) * 2015-11-20 2017-08-02 Henkel Ag & Co Kgaa Hair care agents containing casein hydrolysate for improving hair structure
WO2020127409A1 (fr) * 2018-12-19 2020-06-25 Société des Produits Nestlé S.A. Composition pour prévenir ou réduire la perte d'eau transépidermique et améliorer la fonction barrière de la peau
US12064506B2 (en) 2018-12-19 2024-08-20 Societe Des Produits Nestle S.A. Composition for preventing or reducing transepidermal water loss and improving skin barrier function

Also Published As

Publication number Publication date
JP2008504319A (ja) 2008-02-14
KR101371911B1 (ko) 2014-03-10
US20080063674A1 (en) 2008-03-13
KR20070027634A (ko) 2007-03-09
ATE551048T1 (de) 2012-04-15
EP1922054B1 (fr) 2012-03-28
ES2380940T3 (es) 2012-05-21
CN1976676B (zh) 2010-11-17
EP1922054A2 (fr) 2008-05-21
WO2006000350A3 (fr) 2006-07-13
KR20130010913A (ko) 2013-01-29
CN1976676A (zh) 2007-06-06

Similar Documents

Publication Publication Date Title
EP1922054B1 (fr) Compositions cosmétiques contenant d'hydrolysats de protéine
US8394855B2 (en) Cosmetic compositions
US20100286278A1 (en) Composition comprising an HDAC inhibitor in combination with a retinoid
EP2117652B1 (fr) Compositions cosmétiques
US20070270472A1 (en) Amino, Amino Acid or Peptide Conjugates of Retinoic Acid
EP3206659B1 (fr) Utilisation cosmétique d'une composition contenant de l'acide 10-hydroxystéarique
EP2522331A1 (fr) Utilisation de resvératrol et nicotinamide
US20070243146A1 (en) Vitamin K1 as Energizer in Cosmetic Formulations
EP1926703B1 (fr) Nouveaux derives d'acide carboxylique
EP2522328A1 (fr) Utilisation de resvératrol et ascorbyl-2-glucoside

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005770871

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5869/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 11597165

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020067027480

Country of ref document: KR

Ref document number: 200580021441.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007518495

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWP Wipo information: published in national office

Ref document number: 1020067027480

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 11597165

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005770871

Country of ref document: EP